Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sight Sciences (SGHT)
NASDAQ:SGHT
Sight Sciences (SGHT) Stock Price & Analysis
65 Followers
SGHT Stock Chart & Stats
Day’s Range$5.29 - $5.52
52-Week Range― - ―
Previous Close$5.53
Volume96.92K
Average Volume (3M)N/A
Market Cap
$262.63M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 07, 2024EPS Estimate
-$0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$5.67Price Target Upside6.98% Upside
Rating ConsensusHold
Number of Analyst Covering4
Sight Sciences News
PremiumPress Releases
Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma
Ownership Overview
53.83% Insiders
10.43% Mutual Funds
11.40% Other Institutional Investors
24.35% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SGHT FAQ
What was Sight Sciences’s price range in the past 12 months?
Currently, no data Available
What is Sight Sciences’s market cap?
Currently, no data Available
When is Sight Sciences’s upcoming earnings report date?
Sight Sciences’s upcoming earnings report date is May 07, 2024 which is in 18 days.
How were Sight Sciences’s earnings last quarter?
Sight Sciences released its earnings results on Mar 07, 2024. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.318 by $0.098.
Is Sight Sciences overvalued?
According to Wall Street analysts Sight Sciences’s price is currently Undervalued.
Does Sight Sciences pay dividends?
Sight Sciences does not currently pay dividends.
What is Sight Sciences’s EPS estimate?
Sight Sciences’s EPS estimate is -$0.28.
How many shares outstanding does Sight Sciences have?
Currently, no data Available
What happened to Sight Sciences’s price movement after its last earnings report?
Sight Sciences reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.318. Following the earnings report the stock price went up 6.087%.
Which hedge fund is a major shareholder of Sight Sciences?
Among the largest hedge funds holding Sight Sciences’s share is First Eagle Investment Management LLC. It holds Sight Sciences’s shares valued at N/A.
---
Sight Sciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.67 (6.98% Upside)
$5.67 (6.98% Upside)
Blogger Sentiment
Bullish
SGHT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 6.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $324.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 9.1%
Last 30 Days ▼ 9.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-39.76%
12-Months-Change
Fundamentals
Return on Equity
-39.64%
Trailing 12-Months
Asset Growth
-21.79%
Trailing 12-Months
Company Description
Sight Sciences
Sight Sciences Inc is a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease. The company's product portfolio features the OMNI Surgical System, a dually-indicated device that facilitates the performance of both trabeculotomy and viscoelastic delivery. The company's non-surgical product portfolio consists of TearCare system which is commercially available for both ophthalmologists and optometrists.
---
SGHT Earnings Call
Q4 2024
0:00 / 0:00
---
SGHT Stock 12 Months Forecast
Average Price Target
$5.67
▲(6.98% Upside)
Technical Analysis
Best Analysts Covering SGHT
1 Year
1 Year Success Rate
4/7 ratings generated profit
1 Year Average Return
+31.59%
assigned a buy rating last month
Copying Thomas Stephan's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +31.59% per trade.
---